The anti-hepatitis B (anti-HBV) activities of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (2'-deoxy-3'-thia-5-fluorocytosine [FTC]) were studied by using an HBVtransfected cell line (HepG2 derivative 2.2.15, subclone P5A). The (-) isomer was found to be a potent inhibitor of viral replication, with an apparent 50% inhibitory concentration of 10 nM, whfle the (+) isomer was found to be considerably less active. Both isomers showed miimal toxicity to HepG2 cells (50% inhibitory concentration, >200 a.M) and showed minimal toxicity in the human bone marrow progenitor cell assay. In accord with the cellular antiviral activity data, the 5'-triphosphate of (-)-FIC inhibited viral DNA synthesis in an endogenous HBV DNA polymerase assay, while the 5'-triphosphate of the (+) isomer was inactive.
Hepatitis B virus (HBV), the causative agent of acute and chronic hepatitis, directly affects about 5% of the world's population. Chronic carriers of HBV are at an increased risk of liver damage that, in the worst cases, can lead to cirrhosis of the liver and/or to hepatocellular carcinoma. Vaccination against HBV is one way to effectively prevent HBV infection. However, vaccination is not an effective therapy for the estimated 200 million chronic carriers. Although several antiviral agents such as alpha interferon, adenine arabinoside monophosphate, and acyclovir have been tested as therapeutic agents, only alpha interferon has demonstrated some promise (7, 8, 9, 17, 23, 25) .
The replication cycle of hepadnaviruses includes the reverse transcription of an RNA template (6) . This process is catalyzed by a polymerase that shares significant sequence homology with the reverse transcriptase from retroviruses (17) . As a consequence, it has been demonstrated that a number of compounds that inhibit human immunodeficiency virus (HIV) replication in vitro (for example, 2',3'-dideoxycytidine) also inhibit HBV replication in vitro (4, 14, 15, 18, 24) . These agents await further study to determine their usefulness as therapeutic agents for the treatment of HBV infections.
Here we report the anti-HBV activities, cytotoxicities, and anabolism of the resolved enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC) (Fig. 1) . The anti-HBV activity of the racemic material has been reported previously (4) . Our results show that the * Corresponding authors. antiviral activity of the racemic mixture can be attributed to the 5'-triphosphate of the (-) isomer.
MATERIALS AND METHODS
Compounds. (±)-FTC and racemic 2'-deoxy-3'-thiacytidine (BCH-189; Fig. 1 ) were synthesized by D. Liotta, J. Wurster, and L. Wilson. Separation of the enantiomers was carried out by formation of the 5'-O-butyl ester of the racemic mixture and selective hydrolysis of the (+) enantiomer by using pig liver esterase to give 95% enantiomerically pure (+)-FTC or (+)-BCH-189. The 5'-O-butyl esters of (-)-FTC and (-)-BCH-189, which are not substrates for pig liver esterase, were hydrolyzed chemically to give >99% enantiomerically pure compound. The 5'-triphosphates of (-)-and (+)-FTC were synthesized by S. Hopkins and J. Wilson as described previously (26) . The Hybridization of DNA. 32P-labeled riboprobes, which were used for the detection of plus-or minus-strand HBV DNA, were synthesized by using the plasmid pGEMEX-1 of HBV (prepared at Burroughs Weilcome Co. by T. Powdrill) as the template. Hybridization and washing conditions were as described previously (11, 20) . The (20) .
(ii) Intracellular HBV DNA. After 10 days of incubation with drug, total intracellular DNA was isolated (4, 24 (5) .
Anabolism of(±)-FTC, (+)-FIJC, and (-)-FIC. Anabolism studies were performed by using HepG2-derivative 2.2.15, subclone P5A, cells. Cells were seeded into 75-cm2 flasks containing GIBCO RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, so that the cell culture was 30% confluent (107 total cell number). Twenty-four hours later, 20 p,M (±), (+), or (-) enantiomer of FTC was added and the cultures were incubated for an additional 24 or 48 h at 37°C. Following the incubation, cells were washed twice with 5 ml of ice-cold phosphate-buffered saline and extracted in situ with 3 ml of ice-cold 80% acetonitrile. After incubating on ice for 5 min, the extracts were centrifuged at 2,000 x g for 10 min at 4°C to remove cellular debris. All extracts were then dried with a Savant Speed-Vac. The dried extracts were resuspended in 500 ,ul of deionized water. The extracts were analyzed by ion-exchange HPLC by using an Alltech Partisil (10 ,u) SAX column Deoxycytidine kinase assays. Calf thymus deoxycytidine kinase (EC 2.7.1.40) was purified from frozen calf thymus (Pel-Freez Biologicals, Rogers, Ark.) as described previously (13) by using streptomycin sulfate, protamine sulfate, and ammonium sulfate fractionations; this was followed by chromatography on Sephacryl S-200 and Whatman P-11 cellulose phosphate. The resulting preparation was concentrated by precipitation with ammonium sulfate (0.516 g/ml), and the precipitate was dissolved in 0.1 M Tris-HCl buffer (pH 7.6) containing 5 mM dithiothreitol. The concentrated enzyme solution was stored at -70°C and had a specific activity of 18 nmollmin/mg of protein. Deoxycytidine kinase was assayed spectrophotometrically at 25°C as described previously (13) . Kinetic constants were determined from initial velocity analysis (2) .
Deoxycytidylate kinase assays. Calf thymus deoxycytidylate kinase (EC 2.7.4.14) was partially purified from frozen calf thymus (Pel-Freez Biologicals) following the procedure of Seagrave and Reyes (22) , with the following modifications. Thawed calf thymus was blended in buffer A (25 mM potassium phosphate [pH 7 .5], 10 mM dithiothreitol, 1 mM MgCl2, 10% glycerol), and crude extract was recovered as the supernatant of a 27,000 x g centrifugation. The protamine sulfate step was replaced with a streptomycin sulfate precipitation step (crude extract was made to 10% streptomycin sulfate and dCMP kinase remained in the resulting supernatant). Subsequently, dCMP kinase was precipitated by a 55 to 85% ammonium sulfate fractionation. The dialyzed redissolved pellet was applied to Affi-Gel Blue gel resin (Bio-Rad). The resin was washed with buffer A, and then dCMP kinase was eluted with a gradient of 0 to 1 M KCl in buffer A. Finally, the dialyzed pool was reapplied to a smaller Affi-Gel Blue gel column, the resin was washed with 1 mM ATP in buffer A, and dCMP kinase was eluted with 1 VOL. 36, 1992 mM ATP-1 mM dCMP in buffer A. The final preparation was purified 670-fold compared with the purity of the crude extract. Nucleoside monophosphate kinase activities were assayed spectrophotometrically as described previously (16) Deamination of (-)-and (+)-FTC by CD was measured by reversed-phase HPLC as described above by using 25 mM ammonium phosphate (pH 3.0) and 9% acetonitrile. The isosbestic wavelength of 277 nm was monitored to determine the ratio of product to substrate. A colorimetric method (1) to determine product formation (ammonia) was used with the purified Eschenchia coi CD (12 (3, 000 Ci/mmol; final concentration, 33 nM; Dupont NEN, Boston, Mass.). Reactions were incubated at 3rC for 1 h and were stopped by adding 50 mM EDTA. SDS was added to a final concentration of 1%, and proteinase K was added to a final concentration of 1 mg/ml. After incubation at 37C for 1 h, samples were extracted with phenol-chloroform and precipitated with ethanol. DNAwas resuspended in gel buffer (0.04 M Tris-acetate, 0.001 M EDTA) and separated by electrophoresis through a 1.5% agarose gel. The gel was dried and exposed to a phosphorimaging screen (10) . The image that was obtained by using a Molecular Dynamics Phosphorimager (10) is shown in Fig. 3 . Table 2) .
Compaative cyotxicitie of (±)-FrC, (+)-FC, and (-)-FTC. The cytotoxicities of (-)-FTC, (+)-FTC, and (±)-FTC were compared in a cell growth assay by using HepG2 2.2.15, subclone P5A, cells and an in vitro human bone marrow progenitor cell assay. Little or no toxicity was exhibited by these compounds in the PSA growth inhlbition assay. All ICsO were greater than 200 pM. Only in the human in vitro bone marrow assay were toxicity differences observed ( in the P5A cells (Fig. 2) . The ability of P5A cells to phosphorylate both (-)-and (+)-FTC to the corresponding 5'-triphosphate forms was also investigated (Fig. 2) . Com Phosphorylation of (-)-and (+)-FTC by deoxycytidine kinase and deoxycytidylate kinase. The structural similarity of (-)-FTC and deoxycytidine suggested that deoxycytidine kinase might catalyze the phosphorylation of this analog to the monophosphate derivative. When (-)-FTC and (+)-FTC were incubated with deoxycytidine kinase purified from calf thymus, both analogs served as substrates for the enzyme and had similar apparent Km (Kin') values (Table 3) . However, the apparent Vmax (Vmax') for (-)-FTC was approximately fourfold greater than that for (+)-FTC. Both of the 5'-monophosphate forms of (-)-FTC and (+)-FTC were substrates for deoxycytidylate kinase (Table 3 ). The Km' Table 3 . (+)-FTC was a significantly better substrate for both purified enzymes.
DISCUSSION
Racemic FTC is a potent inhibitor of HBV replication in vitro, as shown here and as reported previously (4) . Testing of the resolved enantiomers has revealed (-)-FTC to be approximately 40-fold more potent than (+)-FTC. It is possible that the (+) isomer has no intrinsic activity and that the apparent activity is due to the 4% contamination with the (-) isomer.
With the exception of 2'-CDG, which is highly toxic, (-)-FTC is one of the most potent anti-HBV compounds identified to date in cell culture. The intrinsic lack of activity suggested for (+)-FTC in cell culture is supported by the results of the endogenous DNA polymerase assay in which the 5'-triphosphate of (-)-FTC, but not that of (+)-FTC, is an inhibitor of DNA polymerase activity. Diminished activity of the (+) isomer has also been seen against HIV type 1 in cellular assay systems (21) . However, the difference in the anti-HIV activities of the two isomers is only 10-fold. In addition, the 5'-triphosphates of (-)-and (+)-FTC have comparable K1 values (2.8 and 8.6 ,uM, respectively) for purified HIV type 1 reverse transcriptase (21) . Therefore, the differential activities of the two isomers cannot be attributed to differential recognition by the HIV reverse transcriptase. One possible explanation suggested by the anabolism studies in HepG2 cells is that the (-) isomer is more extensively phosphorylated. Although HBV and HIV replication both involve reverse transcription of an RNA template and HBV DNA polymerase and HIV type 1 reverse transcriptase share sequence homology (18) , the enantioselectivity of the HBV DNA polymerase suggests that there may be significant differences in the topologies of the substrate binding sites of the two enzymes.
Neither (-)-nor (+)-FTC showed toxicity toward the parental human hepatoma cell line HepG2 (IC50s, >200 FM).
In the human bone marrow progenitor cell assay, (- explain the difference in the toxicity profiles resulting from substitution of F for H at the 5' position. Since the unphosphorylated (-)-FTC did not inhibit HBV DNA polymerase, the antiviral activity of the compound is probably dependent on conversion to the corresponding 5'-triphosphate. Anabolism experiments carried out in P5A cells showed that both (-)-and (+)-FTC are converted to the corresponding 5'-triphosphate derivatives. However, (-)-FTC is anabolized more readily than is (+)-FTC. These results suggest that the differences in activities against HIV type 1 seen in cellular assay systems may be explained, in part, by the difference in substrate efficiency for deoxycytidine kinase and deoxycytidylate kinase that exists between (-)-and (+)-FTC (Table 3) .
One concern for these cytidine analogs was the possibility of catabolism by CD to give the corresponding uridine analog. The uridine analogs of FTC have been shown to be inactive against HBV in cellular assays (4) . In addition, the uridine analog of FTC is a potential precursor of 5-fluorouracil via cleavage of the glycosidic linkage. Studies of the action of CD on FTC (Table 3) indicated that (+)-FTC but not (-)-FTC is a substrate for mammalian CD. These results are in contrast to an earlier report in which inhibitors of CD and deoxycytidine deaminase were found not to increase the antiviral efficacy of (±)-FTC in human hepatoma cells (4).
The conclusion was that no deamination occurred. However, our data suggest that deamination of (+)-FTC could have occurred, but because (+)-FTC has little or no anti-HBV activity, there was no effect on the apparent potency of (±)-FTC.
In summary, (-)-FTC is a potent and selective anti-HBV compound. The site of action appears to be the virally encoded DNA polymerase. Activity at the polymerase requires the compound to be phosphorylated at the 5' position. This phosphorylation occurs in HBV-infected HepG2 cells where substantial levels of the 5'-triphosphate are formed. Although there is a possibility that (-)-FTC is deaminated by CD to the inactive uridine derivative, results of the present study show that the compound is a poor substrate for the enzyme. Catabolic enzymes preferentially recognize the 1-13-D configuration of the (+) isomer, while the anabolic enzymes and the polymerases prefer the 1-i-L configuration of the (-) isomer. The selective activity and favorable enzymatic profile of (-)-FTC indicate that this compound is worthy of additional investigation for the treatment of HBV infections.
